此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

2026年11月9日 更新者:ViiV Healthcare

A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

研究概览

研究类型

介入性

注册 (估计的)

75

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).

  • Male or female:

    1. Male Participants:

      No restrictions for male participants.

    2. A female participant (female sex assigned at birth) is eligible to participate if:

They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
  • A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
  • Clinically significant abnormal blood pressure at Screening.
  • Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
  • History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
  • History of seizure(s) and / or other clinically significant neurological conditions.
  • Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
  • Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
  • Participant is mentally or legally incapacitated.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
  • Unable to refrain from the use of prescription or non-prescription medications.
  • Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
  • Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
  • Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
  • Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
  • Current enrollment or past participation in this clinical study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
  • Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
  • Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
  • Positive Hepatitis C antibody test result at Screening.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
  • Regular alcohol consumption within 6 months prior to Screening.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
  • Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
  • Prior exposure to VH4011499 or Lenacapavir in any formulation..
  • Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
  • Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1: VH4011499 + Ritonavir

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.

VH4011499 is administered to the participants based on the protocol schedule.

Ritonavir is administered to the participants based on the protocol schedule.

实验性的:Cohort 2: VH4011499 + Efavirenz

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.

VH4011499 is administered to the participants based on the protocol schedule.

Efavirenz is administered to the participants based on the protocol schedule.

实验性的:Cohort 3: VH4011499 + Carbamazepine

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.

VH4011499 is administered to the participants based on the protocol schedule.

Carbamazepine is administered to the participants based on the protocol schedule.

实验性的:Cohort 4: VH4011499 + Metformin + Digoxin

Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Metformin is administered to the participants based on the protocol schedule.

Digoxin is administered to the participants based on the protocol schedule.

实验性的:Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin

Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Rosuvastatin is administered to the participants based on the protocol schedule.

Pitavastatin is administered to the participants based on the protocol schedule.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Cmax of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
Day 26
Cmax of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
Day 37
Cmax of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
Day 41
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-t) of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
Day 26
AUC(0-t) of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
Day 37
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
Day 41
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
Day 26
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
Day 37
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
Day 41
Cmax of Metformin when administered alone
大体时间:Day 1
Day 1
Cmax of Metformin when co-administered with VH4011499
大体时间:Day 16
Day 16
AUC(0-t) of Metformin when administered alone
大体时间:Day 1
Day 1
AUC(0-t) of Metformin when co-administered with VH4011499
大体时间:Day 16
Day 16
AUC(0-inf) of Metformin when administered alone
大体时间:Day 1
Day 1
AUC(0-inf) of Metformin when co-administered with VH4011499
大体时间:Day 16
Day 16
Cmax of Digoxin when administered alone
大体时间:Day 1
Day 1
Cmax of Digoxin when co-administered with VH4011499
大体时间:Day 16
Day 16
AUC(0-t) of Digoxin when administered alone
大体时间:Day 1
Day 1
AUC(0-t) of Digoxin when co-administered with VH4011499
大体时间:Day 16
Day 16
AUC(0-inf) of Digoxin when administered alone
大体时间:Day 1
Day 1
AUC(0-inf) of Digoxin when co-administered with VH4011499
大体时间:Day 16
Day 16
Cmax of Rosuvastatin when administered alone
大体时间:Day 5
Day 5
Cmax of Rosuvastatin when co-administered with VH4011499
大体时间:Day 22
Day 22
AUC(0-t) of Rosuvastatin when administered alone
大体时间:Day 5
Day 5
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
大体时间:Day 22
Day 22
AUC(0-inf) of Rosuvastatin when administered alone
大体时间:Day 5
Day 5
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
大体时间:Day 22
Day 22
Cmax of Pitavastatin when administered alone
大体时间:Day 1
Day 1
Cmax of Pitavastatin when co-administered with VH4011499
大体时间:Day 17
Day 17
AUC(0-t) of Pitavastatin when administered alone
大体时间:Day 1
Day 1
AUC(0-t) of Pitavastatin when co-administered with VH4011499
大体时间:Day 17
Day 17
AUC(0-inf) of Pitavastatin when administered alone
大体时间:Day 1
Day 1
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
大体时间:Day 17
Day 17

次要结果测量

结果测量
措施说明
大体时间
Number of participants with adverse events (AEs), overall and by grade.
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with AEs leading to study treatment discontinuation
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
大体时间:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Tmax of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
Day 26
Tmax of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
Day 37
Tmax of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
Day 41
Apparent oral clearance (CL/F) of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
CL/F of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
Day 26
CL/F of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
Day 37
CL/F of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
Day 41
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
t1/2 of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
Day 26
t1/2 of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
Day 37
t1/2 of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
Day 41
Cmax of VH4011499 when co-administered with Metformin and Digoxin
大体时间:Day 16
Day 16
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
大体时间:Day 16
Day 16
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
大体时间:Day 16
Day 16
Cmax of Ritonavir when co-administered with VH4011499
大体时间:Day 26
Day 26
AUC(0-t) of Ritonavir when co-administered with VH4011499
大体时间:Day 26
Day 26
AUC(0-inf) of Ritonavir when co-administered with VH4011499
大体时间:Day 26
Day 26
Cmax of Efavirenz when co-administered with VH4011499
大体时间:Day 37
Day 37
AUC(0-t) of Efavirenz when co-administered with VH4011499
大体时间:Day 37
Day 37
AUC(0-inf) of Efavirenz when co-administered with VH4011499
大体时间:Day 37
Day 37
Cmax of Carbamazepine when co-administered with VH4011499
大体时间:Day 41
Day 41
AUC(0-t) of Carbamazepine when co-administered with VH4011499
大体时间:Day 41
Day 41
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
大体时间:Day 41
Day 41
Cmax of VH4011499 when co-administered with Rosuvastatin
大体时间:Day 22
Day 22
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
大体时间:Day 22
Day 22
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
大体时间:Day 22
Day 22
Cmax of VH4011499 when co-administered with Pitavastatin
大体时间:Day 17
Day 17
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
大体时间:Day 17
Day 17
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
大体时间:Day 17
Day 17

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月16日

初级完成 (估计的)

2027年3月12日

研究完成 (估计的)

2027年3月12日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅